Pepgen Corporation

Chih-Ping Liu

Lorelie H Villarete

Yoshihiro Sokawa

Stephen Kirnon

Interferon-alpha (IFN&#x3b1;) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and/or antitumor agents. In one embodiment, the IFN&#x3b1; analog protein has an amino acid sequence that differs from a native human IFN&#x3b1; interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN&#x3c4;) protein. Methods of combination therapy are also described.

Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs

Interferon-alpha (IFN&#x3b1;) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFN&#x3b1; analog protein has an amino acid sequence that differs from a native human IFN&#x3b1; interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN&#x3c4;) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFN&#x3b1; analog protein are also described.

Low-toxicity, long-circulating human interferon-alpha PEGylated mutants

A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFN&#x3c4;) at a dose sufficient to increase the IL-10 level.

Method of treating IL-10 deficiency

A method for treating a condition responsive to interferon therapy in a human subject is described. The method includes orally administering interferon-tau to the intestinal tract in an amount effective to produce an increase in the subject's blood 2', 5&#x2032;-oligoadenylate synthetase (OAS) level, relative to the OAS level in the subject in the absence of interferon-tau.

Method of treatment using interferon-tau

Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN&#x3c4; are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN&#x3c4; is described. IFN&#x3c4; is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN&#x3c4;.

A method of monitoring treatment of HCV by oral administration of ovine IFN-&#x3c4; is disclosed. The method includes measuring the blood levels of 2',5&#x2032;-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-&#x3c4; until a measurable increase in blood 2&#x2032;,5&#x2032;-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-&#x3c4;, in a dosage effective to stimulate bloodstream levels of 2&#x2032;,5&#x2032;-oligoadenylate synthetase.

Growing community of inventors

San Francisco, CA, United States of America

Chih-Ping Liu